Clinical Trials · NCT02127437

Lanreotide In Polycystic Kidney Disease Study

CompletedPhase 3Lanreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
159
Start date
Sep 2014
Locations
1 site, France
Primary endpoint
Glomerular filtration rate (GFR)
View Lanreotide compound reference